The persistent threat of Ebola virus disease outbreaks in Central and West Africa — compounded by the potential for international spread and the devastating mortality rates of 25-90% in untreated cases — is driving unprecedented investment in prophylactic treatment strategies, with the Prophylactic Ebola Treatment Market reflecting monoclonal antibody platforms as the most promising...